Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Collegium Pharmaceutical, Inc. - Common Stock (NQ:COLL)

32.51 -0.91 (-2.72%)
Streaming Delayed Price Updated: 3:13 PM EDT, Mar 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Collegium Pharmaceutical, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Collegium to Acquire AZSTARYS® from Corium Therapeutics, Strengthening Position in ADHD and Accelerating Growth Trajectory
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Collegium to Present New Real-World Data at PainConnect 2026
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Paris Hilton Shares Her Experience with JORNAY PM and Launches New 'Embrace Your Sparkle' Campaign with Collegium to Empower the ADHD Community
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Collegium to Participate in Upcoming Investor Conferences
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Collegium Reports Fourth Quarter and Full-Year 2025 Financial Results
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Boston Legacy FC Announces Sensory Room Sponsorship with Collegium Pharmaceutical
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Collegium to Report Fourth Quarter and Full-Year 2025 Financial Results on February 26, 2026
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Collegium to Present Four Real-World Data Posters at APSARD 2026 Annual Conference
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Collegium Provides 2026 Financial Guidance and Business Update
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Collegium Announces the Closing of $980 Million Syndicated Credit Facility
Five-Year Financing with Favorable Terms that Significantly Reduce Interest Rate 
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Collegium to Participate in Upcoming Investor Conferences
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Collegium Reports Third Quarter 2025 Financial Results; Raises 2025 Guidance
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Paris Hilton Collaborates with Collegium Pharmaceutical to Share Her Personal ADHD Journey and Experience with Treatment
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Collegium to Report Third Quarter 2025 Financial Results on November 6, 2025
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Collegium Announces Poster Presentations at the American Academy of Child & Adolescent Psychiatry and Neuroscience Education Institute Conferences
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Collegium to Celebrate 10-Year Anniversary with Nasdaq Opening Bell Ringing
– Collegium to Ring Nasdaq Opening Bell on October 14, 2025 – 
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Collegium to Participate in Upcoming Investor Conferences
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Collegium to Present Nine Real-World Data Posters at PAINWeek 2025 Annual Meeting
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Collegium Reports Second Quarter 2025 Financial Results; Raises 2025 Outlook
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Collegium to Report Second Quarter 2025 Financial Results on August 7, 2025
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Collegium Announces $150 Million Share Repurchase Program
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Collegium to Participate in Upcoming Investor Conferences
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:PFE),(NASDAQ:COLL),(NYSE:TEVA),(NYSE:EBS) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
News headline image
Collegium Announces $25 Million Accelerated Share Repurchase Program
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030
From FN Media Group LLC
Via GlobeNewswire
News headline image
Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Collegium to Report First Quarter 2025 Financial Results on May 8, 2025
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Collegium to Present Real-World Data at PainConnect 2025, the American Academy of Pain Medicine’s Annual Meeting
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board
From Avalo Therapeutics
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.